BGLC Quote, Financials, Valuation and Earnings

Century Aluminum Co. has a net margin of -27.87% compared to BioNexus Gene Lab Corp.'s net margin of 1.68%. BioNexus Gene Lab Corp.'s return on equity of -28.84% beat Century Aluminum Co.'s return on equity of 10.05%.

BioNexus Gene Lab Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Century Aluminum Co. has an analysts' consensus of $35.00 which suggests that it could grow by 15.83%. Given that Century Aluminum Co. has higher upside potential than BioNexus Gene Lab Corp., analysts believe Century Aluminum Co. is more attractive than BioNexus Gene Lab Corp..

BioNexus Gene Lab Corp. has a beta of 3.791, which suggesting that the stock is 279.054% more volatile than S&P 500. In comparison Century Aluminum Co. has a beta of 2.285, suggesting its more volatile than the S&P 500 by 128.528%.

BioNexus Gene Lab Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Century Aluminum Co. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNexus Gene Lab Corp. pays -- of its earnings as a dividend. Century Aluminum Co. pays out -- of its earnings as a dividend.

BioNexus Gene Lab Corp. quarterly revenues are $2.5M, which are smaller than Century Aluminum Co. quarterly revenues of $632.2M. BioNexus Gene Lab Corp.'s net income of -$709K is lower than Century Aluminum Co.'s net income of $10.6M. Notably, BioNexus Gene Lab Corp.'s price-to-earnings ratio is -- while Century Aluminum Co.'s PE ratio is 38.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNexus Gene Lab Corp. is 0.78x versus 1.20x for Century Aluminum Co.. Usually stocks with elevated PS ratios are considered overvalued.

Paramount Gold Nevada Corp. has a net margin of -27.87% compared to BioNexus Gene Lab Corp.'s net margin of --. BioNexus Gene Lab Corp.'s return on equity of -28.84% beat Paramount Gold Nevada Corp.'s return on equity of -34.36%.

BioNexus Gene Lab Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Paramount Gold Nevada Corp. has an analysts' consensus of $1.70 which suggests that it could grow by 46.55%. Given that Paramount Gold Nevada Corp. has higher upside potential than BioNexus Gene Lab Corp., analysts believe Paramount Gold Nevada Corp. is more attractive than BioNexus Gene Lab Corp..

BioNexus Gene Lab Corp. has a beta of 3.791, which suggesting that the stock is 279.054% more volatile than S&P 500. In comparison Paramount Gold Nevada Corp. has a beta of 1.319, suggesting its more volatile than the S&P 500 by 31.91%.

BioNexus Gene Lab Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Paramount Gold Nevada Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNexus Gene Lab Corp. pays -- of its earnings as a dividend. Paramount Gold Nevada Corp. pays out -- of its earnings as a dividend.

BioNexus Gene Lab Corp. quarterly revenues are $2.5M, which are larger than Paramount Gold Nevada Corp. quarterly revenues of --. BioNexus Gene Lab Corp.'s net income of -$709K is higher than Paramount Gold Nevada Corp.'s net income of -$4.3M. Notably, BioNexus Gene Lab Corp.'s price-to-earnings ratio is -- while Paramount Gold Nevada Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNexus Gene Lab Corp. is 0.78x versus -- for Paramount Gold Nevada Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Solitario Resources Corp. has a net margin of -27.87% compared to BioNexus Gene Lab Corp.'s net margin of --. BioNexus Gene Lab Corp.'s return on equity of -28.84% beat Solitario Resources Corp.'s return on equity of -20.59%.

BioNexus Gene Lab Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Solitario Resources Corp. has an analysts' consensus of $1.50 which suggests that it could grow by 134.38%. Given that Solitario Resources Corp. has higher upside potential than BioNexus Gene Lab Corp., analysts believe Solitario Resources Corp. is more attractive than BioNexus Gene Lab Corp..

BioNexus Gene Lab Corp. has a beta of 3.791, which suggesting that the stock is 279.054% more volatile than S&P 500. In comparison Solitario Resources Corp. has a beta of 0.440, suggesting its less volatile than the S&P 500 by 55.966%.

BioNexus Gene Lab Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Solitario Resources Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNexus Gene Lab Corp. pays -- of its earnings as a dividend. Solitario Resources Corp. pays out -- of its earnings as a dividend.

BioNexus Gene Lab Corp. quarterly revenues are $2.5M, which are larger than Solitario Resources Corp. quarterly revenues of --. BioNexus Gene Lab Corp.'s net income of -$709K is higher than Solitario Resources Corp.'s net income of -$1.9M. Notably, BioNexus Gene Lab Corp.'s price-to-earnings ratio is -- while Solitario Resources Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNexus Gene Lab Corp. is 0.78x versus -- for Solitario Resources Corp.. Usually stocks with elevated PS ratios are considered overvalued.